RANI THERAPEUTICS HOLDINGS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0 | $0 | $2.7M | $462.0K |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $20.2M | $26.7M | $39.6M | $36.6M | $26.5M | $12.0M |
| SG&A Expense | $19.7M | $23.9M | $26.5M | $26.8M | $27.8M | $5.0M |
| Operating Income | $-38.3M | $-53.3M | $-66.1M | $-63.5M | $-51.6M | $-16.5M |
| Operating Margin | -2,346.0% | -5,186.2% | — | — | -1,899.1% | -3,581.0% |
| Interest Expense | $2.9M | $5.0M | $5.1M | $1.1M | $466.0K | $124.0K |
| Pretax Income | — | — | $-67.9M | $-63.3M | $-53.0M | $-16.7M |
| Income Tax Expense | $0 | $0 | $0 | $70.0K | $41.0K | $35.0K |
| Net Income | $-29.7M | $-30.0M | $-34.0M | $-30.6M | $-8.3M | $-16.7M |
| Net Margin | -1,817.1% | -2,920.0% | — | — | -306.6% | -3,615.4% |
| EPS (Basic) | $-0.45 | $-0.53 | $-0.67 | $-0.64 | $-0.22 | — |
| EPS (Diluted) | $-0.45 | $-0.53 | $-0.67 | $-0.64 | $-0.22 | — |
| Shares Outstanding (Basic) | 66.1K | 57.0K | 51.0K | 47.6K | 39.1K | — |
| Shares Outstanding (Diluted) | 66.1K | 57.0K | 51.0K | 47.6K | 39.1K | — |
| Dividends Per Share | — | — | — | — | — | — |